Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

81 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Phase 1 Study of mTORC1/2 Inhibitor BI 860585 as a Single Agent or with Exemestane or Paclitaxel in Patients with Advanced Solid Tumors.
de Braud F, Machiels JH, Boggiani D, Rottey SWH, Duca M, Laruelle M, Salvagni S, Damian S, Lapeire LDF, Tiseo M, Dermine A, Ould-Kaci M, Braunger J, Rascher J, Fischer D, Hoefler J, Mariani GL, Cresta S. de Braud F, et al. Among authors: mariani gl. Cancers (Basel). 2020 May 31;12(6):1425. doi: 10.3390/cancers12061425. Cancers (Basel). 2020. PMID: 32486385 Free PMC article.
Oral Capecitabine-Vinorelbine is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer.
Vernieri C, Prisciandaro M, Nichetti F, Lobefaro R, Peverelli G, Ligorio F, Zattarin E, Cona MS, Sepe P, Corti F, Manglaviti S, Brambilla M, Re B, Belfiore A, Pruneri G, Celio L, Mariani G, Bianchi GV, Rivoltini L, Capri G, de Braud F. Vernieri C, et al. Cancers (Basel). 2020 Mar 6;12(3):617. doi: 10.3390/cancers12030617. Cancers (Basel). 2020. PMID: 32155941 Free PMC article.
The Pan-Immune-Inflammation-Value Predicts the Survival of Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Breast Cancer Treated with First-Line Taxane-Trastuzumab-Pertuzumab.
Ligorio F, Fucà G, Zattarin E, Lobefaro R, Zambelli L, Leporati R, Rea C, Mariani G, Bianchi GV, Capri G, de Braud F, Vernieri C. Ligorio F, et al. Cancers (Basel). 2021 Apr 19;13(8):1964. doi: 10.3390/cancers13081964. Cancers (Basel). 2021. PMID: 33921727 Free PMC article.
Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles.
Vernieri C, Prisciandaro M, Milano M, Cona MS, Maggi C, Brambilla M, Mennitto A, Fabbroni C, Farè E, Cresta S, Celio L, Mariani G, Bianchi G, Capri G, de Braud F. Vernieri C, et al. Clin Breast Cancer. 2019 Apr;19(2):e306-e318. doi: 10.1016/j.clbc.2018.12.004. Epub 2018 Dec 12. Clin Breast Cancer. 2019. PMID: 30635175
¹⁸F-FLT PET/CT as an imaging tool for early prediction of pathological response in patients with locally advanced breast cancer treated with neoadjuvant chemotherapy: a pilot study.
Crippa F, Agresti R, Sandri M, Mariani G, Padovano B, Alessi A, Bianchi G, Bombardieri E, Maugeri I, Rampa M, Carcangiu ML, Trecate G, Pascali C, Bogni A, Martelli G, de Braud F. Crippa F, et al. Eur J Nucl Med Mol Imaging. 2015 May;42(6):818-30. doi: 10.1007/s00259-015-2995-8. Epub 2015 Feb 12. Eur J Nucl Med Mol Imaging. 2015. PMID: 25673053
Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis.
Lobefaro R, Zattarin E, Nichetti F, Prisciandaro M, Ligorio F, Brambilla M, Sepe P, Corti F, Peverelli G, Ottini A, Beninato T, Mazzeo L, Rea CG, Mariani G, de Braud F, Bianchi GV, Vernieri C, Capri G. Lobefaro R, et al. Ther Adv Med Oncol. 2020 Dec 7;12:1758835920970081. doi: 10.1177/1758835920970081. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33335565 Free PMC article.
The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer.
Vernieri C, Mennitto A, Prisciandaro M, Huber V, Milano M, Rinaldi L, Cona MS, Maggi C, Ferrari B, Manoukian S, Mariani G, Bianchi G, Capri G, Rivoltini L, de Braud F. Vernieri C, et al. Sci Rep. 2018 Jun 7;8(1):8703. doi: 10.1038/s41598-018-27075-z. Sci Rep. 2018. PMID: 29880896 Free PMC article. Clinical Trial.
Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives.
Vernieri C, Milano M, Brambilla M, Mennitto A, Maggi C, Cona MS, Prisciandaro M, Fabbroni C, Celio L, Mariani G, Bianchi GV, Capri G, de Braud F. Vernieri C, et al. Crit Rev Oncol Hematol. 2019 Jul;139:53-66. doi: 10.1016/j.critrevonc.2019.05.001. Epub 2019 May 3. Crit Rev Oncol Hematol. 2019. PMID: 31112882 Review.
81 results